ORYZON to Provide Corporate Progress Updates at Several Events in May
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May...
COVID-19
NervGen Files Management Information Circular and Announces Board of Directors Transition
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General...
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Palisade Bio, Inc. Margery Fischbein Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing,...
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity...
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Conference Call on Tuesday, May 14th, at 4:30 pm ETPOMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies...
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human...
Windtree Therapeutics Regains Compliance with Nasdaq
WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report
FORT MILL, SC / ACCESSWIRE / May 6, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) a MedTech company pioneering products...
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in...
NHI Announces Second Quarter 2024 Dividend
MURFREESBORO, TN / ACCESSWIRE / May 6, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay...
Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System
With This Clearance, Stork Provides Continuous Monitoring of Oxygen Saturation, Pulse Rate, and Skin Temperature, with Alarms, for Babies up...
Zomedica Expands International Reach with CE Certification for VetGuardian(R) System
Key approval paves way for European expansion, tapping into a $4 billion vet services market ANN ARBOR, MI / ACCESSWIRE...
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT /...
Nova Leap Health Corp. Re-engages Acquisition Program with Closing of Strategic Acquisition in Massachusetts
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 06, 2024...
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the...
Rymedi and Precision Genetics Announce Strategic Partnership to Advance Precision Medicine and Healthcare Innovation
GREENVILLE, SC / ACCESSWIRE / May 2, 2024 / Rymedi and Precision Genetics, two leading pioneers in healthcare technology solutions,...
Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform
Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR,...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for...
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel...
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized...